Product Images Sumatriptan Succinate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 4 images provide visual information about the product associated with Sumatriptan Succinate NDC 71205-725 by Proficient Rx Lp, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

chemical-structure - chemical structure

chemical-structure - chemical structure

71205-725-09 - sumatriptan carton 25mg

71205-725-09 - sumatriptan carton 25mg

Sumatriptan Succinate 25mg tablets are a prescription medication used for the treatment of migraines. Each tablet contains 25mg of sumatriptan succinate, and the product is manufactured by Sun Pharmaceutical Industries Ltd. The tablets are white, triangular-shaped, film-coated, and are debossed with "S" on one side and "I" on the other side. The medication should be stored at 20°-25°C (68°-77°F) and kept out of reach of children. The product is relabeled by Proficient Rx LP and is packaged in boxes of 9 tablets with each box containing a unique serial number, lot number, and expiration date. The National Drug Code for this medication is 71205-725-09.*

Sumatriptan-figure-1 - sumatriptan figure 1

Sumatriptan-figure-1 - sumatriptan figure 1

The text describes a graph labeled Figure 1 that shows the estimated probability of achieving initial headache relief within 4 hours of treatment with oral sumatriptan. The graph displays the averages based on pooled data from 3 clinical trials, with probabilities ranging from 80% to 100% depending on the dosage of sumatriptan. The x-axis shows the time in minutes from the initial dose, and the y-axis shows the estimated probability of response. The data is censored at 240 minutes, with patients not achieving response and/or taking rescue within that time frame.*

Sumatriptan-figure-2 - sumatriptan figure 2

Sumatriptan-figure-2 - sumatriptan figure 2

The text describes a figure and table showing the estimated probability of patients taking a second dose of medication to treat migraine within 24 hours after the initial dose of study treatment. The data is obtained from three clinical controlled trials, and the Kaplan-Meier plot shows the efficacy of the treatment in patients not using additional treatments. No remedication was allowed within 2 hours postdose.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.